These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2510135)

  • 21. Differential effects of enzyme induction on antipyrine metabolite formation.
    Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
    Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers.
    Klockowski PM; Lener ME; Sirgo MA; Rocci ML
    Clin Pharmacol Ther; 1990 Oct; 48(4):375-80. PubMed ID: 2146057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning.
    Villa JG; Bayon JE; González-Gallego J
    J Sports Med Phys Fitness; 1999 Sep; 39(3):197-201. PubMed ID: 10573660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety.
    Tordjman T; Estes NA
    Pharmacotherapy; 1987; 7(5):149-63. PubMed ID: 3124082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation.
    Scavone JM; Greenblatt DJ; LeDuc BW; Blyden GT; Luna BG; Harmatz JS
    Pharmacology; 1990; 40(2):77-84. PubMed ID: 2345775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.
    Seyffer R; Eichelbaum M; Jensen JC; Klotz U
    Eur J Clin Pharmacol; 1989; 37(3):231-3. PubMed ID: 2612536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
    Danhof M; Krom DP; Breimer DD
    Xenobiotica; 1979 Nov; 9(11):695-702. PubMed ID: 119355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers.
    Shum L; Pieniaszek HJ; Robinson CA; Davidson AF; Widner PJ; Benedek IH; Flamenbaum W
    J Clin Pharmacol; 1996 Dec; 36(12):1161-8. PubMed ID: 9013374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical exercise and improvement of liver oxidative metabolism in the elderly.
    Mauriz JL; Tabernero B; García-López J; Jorquera F; Villa JG; González-Gallego J
    Eur J Appl Physiol; 2000 Jan; 81(1-2):62-6. PubMed ID: 10552268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of spironolactone on antipyrine metabolism in calves.
    Janus K; Suszycka J
    Res Vet Sci; 1996 Jul; 61(1):87-8. PubMed ID: 8819201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
    Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
    J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.
    Teunissen MW; Bruining GJ; De Jongh BM; Tenkate-Westerhof EW; Breimer DD
    Br J Clin Pharmacol; 1985 Dec; 20(6):703-6. PubMed ID: 4092001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
    van den Broek JM; Teunissen MW; Breimer DD
    Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
    van Bezooijen CF; van Oorschot RM
    J Pharmacol Exp Ther; 1989 Nov; 251(2):683-6. PubMed ID: 2810117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential induction of antipyrine metabolism by rifampicin.
    Toverud EL; Boobis AR; Brodie MJ; Murray S; Bennett PN; Whitmarsh V; Davies DS
    Eur J Clin Pharmacol; 1981; 21(2):155-60. PubMed ID: 7341283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
    Groen K; Breimer DD; van Bezooijen CF
    Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.